Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

NUTLEY, N.J., Jan. 14 /PRNewswire/ -- Following an announcement from Schering-Plough, Roche today affirmed the value of PEGASYS(R) (peginterferon alfa-2a) in combination with ribavirin as the market-leading treatment for patients with hepatitis C, in the United States and globally. Despite clear biases in the design of the "IDEAL" study that potentially favored patients taking Peg-Intron(TM) (peginterferon alfa-2b) regimens - particularly the ribavirin dose reduction protocol - the study results have shown that patients treated with a PEGASYS regimen had a similar chance of being successfully treated for hepatitis C.

"I do not expect that the results of the IDEAL study will meaningfully impact clinical practice, except to inform physicians on the appropriate dosing of Peg-Intron and to reinforce the already widely-accepted view that optimizing ribavirin dosing throughout treatment is critical to achieving success and preventing treatment relapse in hepatitis C," said Douglas Dieterich, M.D., Professor of Medicine in the Division of Hepatology at Mt. Sinai School of Medicine in New York, New York.

In 2001, the U.S. Food and Drug Administration (FDA) required Schering- Plough to conduct a post approval commitment trial to determine if a lower dose of Peg-Intron (1.0 mcg/kg) was as effective as the approved dose of 1.5 mcg/kg, both in combination with identical ribavirin regimens. A third arm was added to the study in which patients received PEGASYS 180 mcg with a different ribavirin dosing schedule. This mismatch of ribavirin dosing introduces several potential biases into the study because experts agree that an optimized dose of ribavirin, with either pegylated interferon, is critical to achieving success in hepatitis C treatment. In particular, maintaining a full dose of ribavirin has shown an important ability to reduce relapse following the end of treatment.

"PEGASYS quickly became the market leader after its launch, based on robust cli
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 2013  The American Society of Addiction Medicine ... the effectiveness of medications for opioid addiction and ... by many state governments and insurance companies. Drug ... car crashes, an epidemic led by misuse of ... safe and effective medications to treat opioid addiction ...
(Date:6/17/2013)... June 17, 2013 ... Pharmaceutical Guidebook: Latest Chinese Regulations for ...      (Logo: http://photos.prnewswire.com/prnh/20130128/590935) ... possesses a fourth population in the ... largest drug markets round the world. ...
(Date:6/17/2013)... Mass. , and SYDNEY ... Inc. (Nasdaq: HTWR ; ASX: HIN), ... support technologies that are revolutionizing the treatment of ... Food and Drug Administration (FDA) has granted conditional ... that allows HeartWare to commence enrollment in an ...
Breaking Medicine Technology:Effective Rx thwarted for deadly opiate epidemic 2China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration 2China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration 3China Pharmaceutical Guidebook: Latest Chinese Regulations for Imported Drug Registration 4HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial 2HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial 3HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial 4
(Date:6/17/2013)... (PRWEB) June 17, 2013 According to a ... Questions Answered,” as more and more information surfaces about the ... should become a vital part of one’s skin care ... and cancer (Go to goo.gl/qTKZQ). , “I agree with ... says Dr. Simon Ourian, Medical Director of Epione Beverly Hills. ...
(Date:6/17/2013)... Santiago de Chile, Chile (PRWEB) June 17, 2013 ... India. It literally means in sanscrit "knowledge or wisdom of ... realms of the spirit and the transformation of consciousness. Its ... living out of harmony with our environment. In order to ... out of harmony and then adopt a life style which ...
(Date:6/17/2013)... 2013 BPI Sports , a ... GNC Award at this year's GNC Franchise Convention held ... recognition is "Partner of the Year." This is the ... past 15 months, the other two being the 2011 ... , BPI continues to pave the way for the ...
(Date:6/17/2013)... June 17, 2013 MelanSol® All Natural ... Naturals LLC, the US distributor for MelanSol®, has partnered ... Bay Area Food Bank to support their efforts ... by seeing that they receive a portion of every ... All Natural Moisturizer. Contributions will be given on sales ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Earlier ... Human Services adopted tough standards to strengthen the ... the Health Insurance Portability and Accountability Act (HIPAA) ... patients’ protection of the privacy of their health ... their health information, while also supporting the government’s ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:Ayurveda Chile Program Offered by Escuela Ayurveda de California in August, 2013 2Health News:GNC Awards Another Prestigious Award to BPI Sports - 2012 Partner of the Year 2Health News:All Natural Sunscreen Fights Hunger 2Health News:Six Tips for Healthcare Providers About the New HIPAA Omnibus Rule 2Health News:Six Tips for Healthcare Providers About the New HIPAA Omnibus Rule 3
... Siemens Healthcare, (http://www.siemens.com/healthcare ) honors the early ... technology at the,2008 Society of Nuclear Medicine (SNM) ... booth (#731) will feature experiences from early,adopters as ... and highlighting,how HD-PET is enabling improved patient care ...
... Be aware of your prostate cancer risk, experts advise , , SUNDAY, ... to themselves, all men should ask three key questions about their ... (NSGC). , The first question: , What could ... a close relative with prostate cancer, like a brother or a ...
... June 15 Therap Services announces the,release of version 7.3 of ... now up and running,with its latest features and enhancements., ... A new ISP Plan module has been introduced for New York ... providers in other states with the appropriate ISP ...
... the June 15th issue of G&D, Dr. Sinisa Urban ... a potential role for the rhomboid enzyme, EhROM1, in ... This discovery posits EhROM1 as a prospective target in ... the global population (500 million people) and represents the ...
... year, about 500 million people worldwide are infected with the ... infectious diseases is second only to malaria. In a new ... and Development , Johns Hopkins researchers may have found a ... that may help the dysentery-causing amoeba evade the immune system. ...
... June 14 Volunteers and staff of the,American Heart ... national television journalist Tim Russert who died suddenly on ... journalist and we are deeply,saddened by this loss," said ... was an ardent champion for those issues that touched,all ...
Cached Medicine News:Health News:A Clearer View of High Definition: Siemens Turns the Spotlight on Pioneers of HD-PET With In-Booth Exhibit at SNM 2008 2Health News:A Health Gift for Men on Father's Day 2Health News:Therap Services Announces Release 7.3 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.3 for the Developmental Disability Community 3Health News:New molecular insight into amboebic dysentery 2Health News:How Montezuma gets his revenge 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: